Education
About Us
Working with TipRanks
Follow Us
Daré Bioscience (DARE)
:DARE
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.43Last Year’s EPS
1.52Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: 7.27%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted Daré Bioscience's strategic moves towards commercialization and revenue generation through an expanded business strategy and new product launches. However, financial challenges such as a working capital deficit and comprehensive loss, along with regulatory hurdles, present significant concerns.Company Guidance
In the recent conference call, Daré Bioscience provided guidance on their strategic direction, highlighting a dual path strategy for product commercialization. They plan to bring four products to market, including their Sildenafil Cream and a monthly hormone therapy, targeting the estimated $4.5 billion hormone therapy market. They aim to record revenue in Q4 2025, capitalizing on a nimble business model that leverages both FDA approval and 503B compounding. Financially, Daré reported a Q1 2025 comprehensive loss of approximately $4.4 million, with general and administrative expenses reduced by 14% and R&D expenses by 31% compared to Q1 2024. They closed the quarter with $10.3 million in cash and a working capital deficit of $9.4 million. The company is actively pursuing strategic partnerships to enhance product access and plans to update stakeholders on these developments, alongside their ongoing pipeline progress, in the coming months.Expanded Business Strategy
Daré Bioscience announced an expanded business strategy leveraging a dual path strategy to commercialize proprietary formulations via 503B compounding while continuing to seek FDA approval. This strategy aims to accelerate revenue generation and provide a path to profitability.
New Product Launches
Daré is planning to launch three more solutions for women, including two vaginal probiotics in 2025 and a proprietary monthly hormone therapy in 2026, targeting a $4.5 billion market.
Decrease in Operating Expenses
The company's general and administrative expenses decreased by 14%, and R&D expenses decreased by 31% compared to Q1 2024, reflecting cost management efforts.
Strategic Partnerships
Daré is seeking multiple strategic partnerships to provide women access to its evidence-based solutions across multiple channels, including collaborations with telehealth providers and online platforms.
Ovaprene Clinical Progress
The pivotal Phase 3 contraceptive efficacy study for Ovaprene is ongoing, with a Data Safety Monitoring Board interim assessment scheduled for July 2025.
DARE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DARE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $2.89 | $2.89 | 0.00% |
Mar 31, 2025 | $2.89 | $2.90 | +0.35% |
Nov 14, 2024 | $3.56 | $3.21 | -9.83% |
Aug 12, 2024 | $3.50 | $4.20 | +20.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Daré Bioscience (DARE) report earnings?
Daré Bioscience (DARE) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Daré Bioscience (DARE) earnings time?
Daré Bioscience (DARE) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DARE EPS forecast?
DARE EPS forecast for the fiscal quarter 2025 (Q2) is -0.43.